# Hepatic Impairment Study

> **NCT00829231** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 45 (actual)

## Conditions studied

- Liver Disease

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)
- **DRUG:** Sorafenib (Nexavar, BAY43-9006)
- **DRUG:** Sorafenib (Nexavar, BAY43-9006)

## Key facts

- **NCT ID:** NCT00829231
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2014-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00829231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00829231, "Hepatic Impairment Study". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00829231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*